Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Zimmer

Showing results (51-60 of 218) with videos related to

Pageof 22
Sort By:
British Journal of Pharmacology|June 16, 2026
Refining the treatment of immune checkpoint inhibitor-associated myocarditis: Challenges, innovations and rechallenge considerationsRaluca I Mincu, Lisa Zimmer, Dimitra Vlachopoulou, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|July 20, 2019
Prognostic factors for pulmonary metastasectomy in malignant melanoma: size mattersJan Viehof, Elisabeth Livingstone, Elena Loscha, et al.
European Journal of Cancer (Oxford, England : 1990)|October 16, 2021
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF<sup>V600</sup> mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trialLisa Zimmer, Elisabeth Livingstone, Angela Krackhardt, et al.
Cancers|July 14, 2023
Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint InhibitionJessica C Hassel, Lisa Zimmer, Thomas Sickmann, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|August 14, 2021
Carl Maximilian Thielmann, Selma Ugurel, Elisabeth Livingstone, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2021
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patientsAnne Zaremba, Alexander M M Eggermont, Caroline Robert, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 24, 2021
Metastatic pigmented epithelioid melanocytoma in a 7-year-old femaleCarl Maximilian Thielmann, Selma Ugurel, Elisabeth Livingstone, et al.
Eneurologicalsci|February 19, 2021
Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapySaskia Bolz, Thivyah Ramakrishnan, Michael Fleischer, et al.
European Radiology|May 1, 2025
Adverse effects of systemic advanced melanoma therapies-do BRAF/MEK inhibitors increase the incidence of mesenteric panniculitis?Marcel Alexander Drews, Alexander Baumgarten, Sebastian Zensen, et al.
Plos One|April 22, 2015
Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infectionWiebke Sondermann, Klaus G Griewank, Bastian Schilling, et al.
Pageof 22

Showing results (51-60 of 218) with videos related to

Sort By:
Pageof 22
British Journal of Pharmacology|June 16, 2026
Refining the treatment of immune checkpoint inhibitor-associated myocarditis: Challenges, innovations and rechallenge considerationsRaluca I Mincu, Lisa Zimmer, Dimitra Vlachopoulou, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|July 20, 2019
Prognostic factors for pulmonary metastasectomy in malignant melanoma: size mattersJan Viehof, Elisabeth Livingstone, Elena Loscha, et al.
European Journal of Cancer (Oxford, England : 1990)|October 16, 2021
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF<sup>V600</sup> mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trialLisa Zimmer, Elisabeth Livingstone, Angela Krackhardt, et al.
Cancers|July 14, 2023
Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint InhibitionJessica C Hassel, Lisa Zimmer, Thomas Sickmann, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|August 14, 2021
Carl Maximilian Thielmann, Selma Ugurel, Elisabeth Livingstone, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2021
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patientsAnne Zaremba, Alexander M M Eggermont, Caroline Robert, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 24, 2021
Metastatic pigmented epithelioid melanocytoma in a 7-year-old femaleCarl Maximilian Thielmann, Selma Ugurel, Elisabeth Livingstone, et al.
Eneurologicalsci|February 19, 2021
Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapySaskia Bolz, Thivyah Ramakrishnan, Michael Fleischer, et al.
European Radiology|May 1, 2025
Adverse effects of systemic advanced melanoma therapies-do BRAF/MEK inhibitors increase the incidence of mesenteric panniculitis?Marcel Alexander Drews, Alexander Baumgarten, Sebastian Zensen, et al.
Plos One|April 22, 2015
Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infectionWiebke Sondermann, Klaus G Griewank, Bastian Schilling, et al.
Pageof 22